Biotech and Pharmaceuticals Pharmaceuticals

  • Mylan said it would buy Abbott Labs' generics business outside the United States in an all-stock transaction valued at about $5.3 billion.

  • Abbvie is 'unique': Pro

    Howard Goldring, founder of Delmore Asset Management, says that Abbvie's increased offer for Shire is "very good" and discusses what a deal would mean for both companies.

  • The fight against Alzheimer's

    CNBC's Meg Tirrell reports there are currently 67 medicines in development for Alzheimer's, with the biggest players in the space including Eli Lilly, Roche/Genentech and Biogen.

  • Big pharma's big battle with Alzheimer's

    CNBC's Meg Tirrell reports on how the pharmaceutical industry is dealing with the Alzheimer's epidemic.

  • Acorda 'firmly on the side of research': CEO

    Ron Cohen, Acorda Therapeutics CEO, discusses merger activity in the pharma sector and whether his company is planning an acquisition.

  • Sarepta to file for approval of Eteplirsen

    The muscular dystrophy drug seems to slow the decline in walking ability, reports CNBC's Meg Tirrell.

  • Allergan CEO comes out swinging

    CNBC's Meg Tirrell reports Allergan CEO David Pyott told "Mad Money" host Jim Cramer Valeant's he is keeping his options open on acquisitions.

  • Narcotics prosecutors say a NYC hospital's former pharmacy chief stole nearly 200,000 oxycodone pills over more than five years.

  • Steps to improve long-term health: Sanofi CEO

    The big driver in this is chronic diseases, says Sanofi CEO Chris Viehbacher, explaining how big pharma is preparing for the onslaught of aging baby boomers heading towards retirement age.

  • Registered nurse JoAnn Brand (L) examines Sham Tavakoli at the Lifelong Medical Marin Adult Day Health Care Center.

    CNBC's Meg Tirrell, takes a look at how America¿s baby boomer generation will likely affect the pharmaceutical industry.

  • Protect yourself from fake medicine

    CNBC's Scott Cohn follows up on his investigation into the high cost of prescription drugs and reports how consumers can protect themselves from getting fake medicine.

  • While there are weaknesses in the alternative market of prescription drugs, the risks are not always as serious as some claim.

  • Internet drugstores and their facilitators may claim to be safe, low-cost alternatives to pharmacies. But consumers need to be cautious.

  • Prescription drugs: Risk vs. cost

    Due to the high cost of prescription drugs, many in the U.S. look overseas to save money. CNBC's Scott Cohn discusses if people are putting themselves at risk or beating big drug companies at their own game.

  • Big pharm wages war against Internet drug sales

    CNBC's Scott Cohn reports many Americans are trying to save money on prescription drugs by buying them online, but big pharma is fighting back.

  • Web page for Pfizer's Elelyso

    Pfizer paid a "nominal fee" to cover expenses related to the facility inspection, and to obtain a certification, a Pfizer spokeswoman said.

  • Actavis completes deal to buy Forest Labs

    The idea is to keep the generic DNA but not the generic margins, says Brent Saunders, Actavis CEO, discussing his company's acquisition of Forest Labs and its long-term growth plans. Saunders also weighs in on corporate tax reform.

  • Wild ride for MannKind's Afrezza

    The FDA approved MannKind's inhaled insulin drug Afrezza. CNBC's Meg Tirrell has the details of the approval.

  • Pfizer to make new AstraZeneca bid?

    Kokou Agbo-Bloua, head of equity and derivative strategy for Europe at BNP Paribas, says that Pfizer is likely to submit another bid to acquire AstraZeneca as a deal would still make "a lot of sense".

  • Vertex CEO on big cystic fibrosis breakthrough

    CNBC's Meg Tirrell speaks to Vertex Pharmaceuticals CEO Dr. Jeffrey Leiden, about its promising two-drug cystic fibrosis treatment, and what it means for sufferers of the disease. Leiden also explains what goes into the pricing of an "orphan drug."